Tumor Cell Or Cancer Cell Patents (Class 435/7.23)
-
Publication number: 20140255430Abstract: The invention described herein relates to the treatment, detection, and diagnosis of various cancers, including esophageal or gastric adenocarcinoma and related metaplasias. The invention also includes a clonal population of Barrett's esophagus progenitor cells and methods of using them for the treatment, detection, and diagnosis of Barrett's esophagus.Type: ApplicationFiled: December 20, 2013Publication date: September 11, 2014Applicants: NATIONAL UNIVERSITY OF SINGAPORE, Agency for Science, Technology and Research (A*Star), Harvard University, Brigham & Women's Hospital, Multiclonal Therapeutics, Inc.Inventors: Wa XIAN, Frank MCKEON, Matthew VINCENT, Christopher CRUM, Khek Yu HO
-
Publication number: 20140255411Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants a which are suitable targets for immunotherapy, cancer therapy, and drug development.Type: ApplicationFiled: March 18, 2013Publication date: September 11, 2014Applicant: COMPUGEN LTD.Inventors: Zurit LEVINE, Amir TOPORIK, Amit NOVIK, Anat COHEN-DAYAG, Avi ROSENBERG, Cynthia KOIFMAN, Dalit LANDESMAN-MILO, Eve MONTIA, Galit ROTMAN, Liat DASSA, Marina BUBIS, Merav BEIMAN, Ofer LEVY, Sergey NEMZER, Shira WALACH, Shirley SAMEACH- GREENWALD, Tania PERGAM, Yaron KINAR
-
Patent number: 8828737Abstract: Methods for using focused light scattering techniques for the optical sensing of biological particles suspended in a liquid medium are disclosed. The optical sensing enables one to characterize particles size and/or distribution in a given sample. This, in turn, allows one to identify the biological particles, determine their relative particle density, detect particle shedding, and identify particle aggregation. The methods are also useful in screening and optimizing drug candidates, evaluating the efficacy and dosage levels of such drugs, and in personalized medicine applications.Type: GrantFiled: July 14, 2009Date of Patent: September 9, 2014Assignee: Invitrox, Inc.Inventor: Don Gabriel
-
Patent number: 8828389Abstract: The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent. The invention also relates to novel amyotrophic lateral sclerosis-specific epitopes and their uses to make antibodies, and to the novel antibodies and uses thereof.Type: GrantFiled: December 7, 2011Date of Patent: September 9, 2014Assignee: Amorfix Life Sciences Ltd.Inventor: Neil Cashman
-
Patent number: 8828671Abstract: Whole cell, simultaneous target and drug-target assay using differentially labeled antibodies and flow cytometry. First antibody binds to total target and second antibody binds to the drug binding site of the target, thus drug binding will competitively inhibit the second antibody allowing for a competitive inhibition assay of drug-target binding. The assay allows for whole cell analysis and even analysis of mixed populations of cells, yet provides detailed kinetic assessment of drug activity.Type: GrantFiled: February 5, 2013Date of Patent: September 9, 2014Assignee: Laboratory Corporation of America HoldingsInventors: Norman B. Purvis, Gregory T. Stelzer
-
Publication number: 20140248283Abstract: The present invention provides and includes monoclonal antibodies (mAbs) preferentially selective for HER2 antigens, hybridoma lines that secrete these HER2 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect HER2 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble or secreted form of HER2. The present invention also includes an antibody or antibody fragment that is capable of reducing the activity of HER2 in at least one form, including a soluble form or a secreted form. The present invention further includes chimeric antibodies, processes for producing monoclonal and chimeric antibodies or monoclonal or chimeric antibodies, and their therapeutic uses, particularly in the detection of cancer most preferentially in human breast, stomach, and colon.Type: ApplicationFiled: May 13, 2014Publication date: September 4, 2014Applicant: ALPER BIOTECH, LLCInventor: Özge Alper
-
Patent number: 8822164Abstract: A biomarker, method, test kit, and diagnostic system for detecting the presence of lymphoma in a person are disclosed. The lymphoma may be Hodgkin's lymphoma or non-Hodgkin's lymphoma. The person may be a high-risk subject. In one embodiment, a plasma sample from a person is obtained. The level of at least one protein listed in Table S3 in the plasma sample is measured. The level of at least one protein in the plasma sample is compared with the level in a normal or healthy subject. The lymphoma is diagnosed based upon the level of the at least one protein in the plasma sample in comparison to the normal or healthy level.Type: GrantFiled: November 30, 2012Date of Patent: September 2, 2014Assignee: Battelle Memorial InstituteInventors: Richard C. Zangar, Susan M. Varnum
-
Patent number: 8822196Abstract: The invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain of a KDR-1121 or DC101 antibody, an extracellular hinge domain, a T cell receptor transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.Type: GrantFiled: May 2, 2013Date of Patent: September 2, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Steven A. Rosenberg, Dhanalakshmi Chinnasamy
-
Patent number: 8821880Abstract: The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to polypeptide antagonists of PLVAP proteins, including humanized and chimeric antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising such polypeptide antagonists.Type: GrantFiled: September 9, 2009Date of Patent: September 2, 2014Assignee: China Synthetic Rubber CorporationInventors: Kuo-Jang Kao, Andrew T. Huang
-
Publication number: 20140243236Abstract: Certain disclosed embodiments of the present invention concern the synthesis, derivatization, conjugation to immunoglobulins and signal amplification based on discrete, relatively short polymers having plural reactive functional groups that react with plural molecules of interest. Reactive functional groups, such as hydrazides, may be derivatized with a variety of detectable labels, particularly haptens. The remaining reactive functional groups may be conjugated directly to a specific binding molecule, such as to the oxidized carbohydrate of the Fc region of the antibody. Disclosed conjugates display large signal amplification as compared to those based on molecules derivatized with single haptens, and are useful for assay methods, particularly multiplexed assays.Type: ApplicationFiled: April 23, 2014Publication date: August 28, 2014Applicant: Ventana Medical Systems, Inc.Inventors: Jerry W. Kosmeder, II, Casey A. Kernag, Donald Johnson, Christopher Bieniarz
-
Publication number: 20140241993Abstract: A chlorotoxin conjugate detectable by fluorescence imaging that allows for intra-operative visualization of cancerous tissues, compositions that include the chlorotoxin conjugate, and methods for using the chlorotoxin conjugate.Type: ApplicationFiled: May 8, 2014Publication date: August 28, 2014Applicants: University of Washington, Fred Hutchinson Cancer Research CenterInventors: Miqin Zhang, Richard G. Ellenbogen, Raymond W. Sze, Omid Veiseh, James Olson, Mandana Veishe, Patrik Gabikian, S-Bahram Bahrami
-
Publication number: 20140242069Abstract: Provided is a method of decreasing the stability of HER2 (human epidermal growth factor receptor 2) in a cell or individual comprising administering an effective amount of an expression or activity inhibitor of KRT19 (cytokeratin 19) to the cell or individual.Type: ApplicationFiled: February 26, 2013Publication date: August 28, 2014Inventors: In-Cheol Shin, Tae-Hoon Lee, Ji-Hyun JU, Kyung-Min Lee, Won-Seok Yang
-
Publication number: 20140242611Abstract: The invention relates to a method for quantifying a protein of interest expressed at the surface of a cell or else present in a tissue sample, said method comprising the use of two ligands capable of binding specifically to a domain of said protein.Type: ApplicationFiled: July 4, 2012Publication date: August 28, 2014Applicant: CISBIO BIOASSAYSInventors: Hervé Bazin, Gérard Mathis
-
Publication number: 20140243295Abstract: The present invention relates to: —use of a 2,3-dihydroimidazo[1,2-c]quinazoline compound, or of a pharmaceutical composition containing same, as a sole active agent, or of a combination of a) said compound or a pharmaceutical composition containing said compound and b) one or more further active agents, for the preparation of a medicament for the treatment or prophylaxis of cancer; —combinations of a) said compound and b) one or more further active agents; —a pharmaceutical composition comprising said compound as a sole active agent for the treatment of breast cancer; —a pharmaceutical composition comprising a combination of a) said compound and b) one or more further active agents; —use of biomarkers involved in the modification of Bel expression, HER family expression and/or activation, PIK3CA signaling and/or loss of PTEN for predicting the sensitivity and/or resistance of a cancer patient to said compound and providing a rationale-based synergistic combination as defined herein to increase sensitivity anType: ApplicationFiled: March 29, 2012Publication date: August 28, 2014Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Ningshu Liu, Claudia Schneider
-
Publication number: 20140242612Abstract: A system and method for analyzing a biomarker in a biological sample is provided. A biological sample is loaded onto a microchip and an enzyme-linked immunosorbent assay specific to the biomarker is performed on the microchip. A color image of the microchip is generated using a mobile device and a color intensity of a selected portion of the color image is determined. The color intensity is correlated with a biomarker concentration using a baseline curve calculation and the concentration of the biomarker is then reported.Type: ApplicationFiled: July 16, 2012Publication date: August 28, 2014Inventors: Shuqi Wang, Utkan Demirci, Bin Ye, Ragip Akbas
-
Patent number: 8815527Abstract: The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state.Type: GrantFiled: April 26, 2011Date of Patent: August 26, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Omar D. Perez, Garry P. Nolan
-
Patent number: 8815517Abstract: The identification and evaluation of mRNA and protein targets associated with mRNP complexes and implicated in the expression of proteins involved in common physiological pathways is described. Effective targets are useful for treating a disease, condition or disorder associated with the physiological pathway.Type: GrantFiled: December 4, 2002Date of Patent: August 26, 2014Assignee: Ribonomics, Inc.Inventors: Jack D. Keene, Scott A. Tenenbaum, Craig C. Carson, William C. Phelps
-
Publication number: 20140234327Abstract: The invention discloses a monoclonal antibody against human non-small cell lung carcinoma and a use of the monoclonal antibody. The monoclonal antibody is secreted by a hybridoma cell strain which is deposited as CCTCC Access Number No.: C201172. It has high yield and high titer, and has specific reactivity against lung adenocarcinoma and squamous carcinoma cell lines. Therefore, the monoclonal antibody may be applied in preparing drugs for treating human non-small cell lung carcinoma.Type: ApplicationFiled: January 12, 2012Publication date: August 21, 2014Inventors: Shiyan Pan, Peijun Huang, Fang Wang
-
Publication number: 20140234326Abstract: The present invention relates to a pharmaceutical composition or an anticancer agent for preventing and treating non-small cell lung cancer, containing a substance for regulating the expression or activity of transmembrane 4 L six family member 4 (TM4SF4). More specifically, the present invention relates to a use of a substance for regulating the expression or activity of TM4SF4 as an anticancer drug or an anticancer agent with respect to non-small cell lung cancer, wherein it was ascertained that it is possible to decrease the growth, metastasis, and infiltration of adenocarcinoma cells and radioresistance by decreasing the expression of TM4SF4 in adenocarcinoma among non-small cell lung cancers and to decrease the growth, metastasis, and infiltration of the cells and radioresistance by increasing the expression of TM4SF4 in other non-small cell lung cancers except adenocarcinoma.Type: ApplicationFiled: October 21, 2011Publication date: August 21, 2014Applicant: KOREA ATOMIC ENERGY RESEARCH INSTITUTEInventors: In-Gyu Kim, Soo Im Choi, Byung-Chul Shin
-
Publication number: 20140235479Abstract: The present invention provides methods of detecting cancer using biomarkers.Type: ApplicationFiled: February 6, 2014Publication date: August 21, 2014Inventors: Ronald A. Depinho, Zhihu Ding, Lynda Chin
-
Publication number: 20140234869Abstract: Methods of isolating, enriching, capturing, identifying, or detecting the presence of, cancerous cells in a sample, e.g., a blood sample from a subject, by detecting the presence of one or more cancer cell surface markers selected from the group consisting of cadherin 1 (CDH1), CDH2, CDH3, CDH4, CDH5, CDH9, CDH11, CDH17, CDH19, protocadherin 9 (PCDH9) and/or PCDH beta 13 (PCDHb13), and optionally an additional cancer cell surface marker, e.g., EpCAM, MUC1, EphB4, EGFR, CEA, and/or HER2.Type: ApplicationFiled: September 28, 2012Publication date: August 21, 2014Inventors: Shyamala Maheswaran, David Tsai Ting, Daniel A. Haber
-
Publication number: 20140234213Abstract: Methods for generating hybrid antibodies are provided.Type: ApplicationFiled: May 29, 2012Publication date: August 21, 2014Inventors: Gregory P. Adams, Heidi H. Simmons, Matthew K. Robinson, Roland Dunbrack, Andreas Lehmann
-
Publication number: 20140234866Abstract: The invention relates to a method for diagnosing a disease state mediated by pathogenic cells. The method comprises the steps of combining with an ex vivo patient sample a composition comprising a conjugate or complex of the general formula Ab-X wherein the group Ab comprises a ligand that binds to the pathogenic cells and the group X comprises an imaging agent, and detecting the pathogenic cells that express a receptor for the ligand using flow cytometry.Type: ApplicationFiled: February 24, 2014Publication date: August 21, 2014Applicant: Purdue Research FoundationInventors: Philip Stewart LOW, Wei HE, Sumith A. KULARATNE
-
Publication number: 20140234867Abstract: Isolated antibodies specifically binding to heterodimers of the Bcl-2 family and uses thereof for detecting presence of Bcl-2 heterodimers in a patient.Type: ApplicationFiled: April 30, 2014Publication date: August 21, 2014Applicant: Eutropics Pharmaceuticals, Inc.Inventors: Michael H. Cardone, Anthony G. Letai
-
Publication number: 20140235714Abstract: The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor. Catecholic butanes cane serve as dual kinase inhibitors for purposes of methods described herein. Subjects can be further treated by co-administering an EGFR inhibitor. The present application also relates to analyzing a sample with respect to levels of IGF-1R and EGFR and comparing levels of IGF-1R and EGFR to a control. Patients can be selected for treatment with a catecholic butane based on the assessment; optionally, patients can be further treated with an EGFR inhibitor, an IGF-1R inhibitor, or both.Type: ApplicationFiled: April 25, 2014Publication date: August 21, 2014Applicant: TriAct Therapeutics, Inc.Inventors: Thomas F. WHITE, Edward F. SCHNIPPER, Dan HOTH
-
Publication number: 20140234297Abstract: The invention provides recombinant protein (e.g., a recombinant antibody or soluble receptor) having (i) a binding domain capable of specific binding to an epitope (for example an antibody variable domains, a receptor, a growth factor, a cytokine, or a fragment of any of the foregoing which is capable of specifically binding the desired epitope) and (ii) an effector domain comprising a constant domain region which is derived from immunoglobulin of a first species which is a companion mammal, e.g. dog, cat, or horse, having engineered substitutions at one or more positions and having an altered interaction with one or more FcRs or other ligands, and optionally enhanced effector function, relative to the parent constant domain region.Type: ApplicationFiled: September 24, 2013Publication date: August 21, 2014Inventor: Genevieve HANSEN
-
Publication number: 20140235707Abstract: The invention provides methods for predicting the efficacy of eribulin, an analog thereof, or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate), in the treatment of a subject suffering from breast cancer by determining the level of particular biomarkers in a sample derived from the subject.Type: ApplicationFiled: March 16, 2012Publication date: August 21, 2014Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Sergei I. Agoulnik, Michael Chapman Byrne, Bruce A. Littefield
-
Publication number: 20140234323Abstract: The present invention relates to antibodies, antibody fragments, and derivatives thereof that specifically bind to TLR3 cell receptors present on the surface of cells. The invention also relates to hybridomas producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to detect TLR3 levels on the surface of cells, and the use of such antibodies and compositions for diagnostic or therapeutic purposes in subjects.Type: ApplicationFiled: May 2, 2014Publication date: August 21, 2014Applicant: Innate PharmaInventors: KARINE CHEMIN, LAURENT GAUTHIER, YANNIS MOREL, CARINE PATUREL, AGNES TISSERANT
-
Publication number: 20140234868Abstract: The present invention relates to glycolipoprotein gintonin, isolated and identified from ginseng, as a natural medicinal-plant-derived ligand acting on LPA1 (lysophosphatidic acid; 1- or 2-acyl-sn-glycerol-3-phosphate), LPA2, LPA3, LPA4 and LPA5 receptors whose efficacy is exhibited physiologically/pharmaceutically via an interaction with subset receptors [LPA1(edg-2), LPA2(edg-4), LPA3(edg-7), LPA4, PLA5] in the EDG (endothelial differentiation gene) family in G protein-coupled receptors (GPCRs) present in the cell membranes of animals including humans.Type: ApplicationFiled: September 19, 2012Publication date: August 21, 2014Applicant: KONKUK UNIVERSITY INDUSTRIAL COOPERATION CORP.Inventors: Seung Yeol Nah, Sung Hee Hwang, Tae Joon Shin, Sun Hye Choi
-
Publication number: 20140234328Abstract: The present invention relates to use of the human Met receptor (also known as “c-Met”) for predicting the efficacy of inhibitors of the HGF-Met pathway, and in particular, anti-HGF antibodies, in the treatment of esophageal and gastric cancer patients. The present invention also relates to methods and kits for predicting the usefulness of anti-HGF antibodies in the treatment of esophageal and gastric cancer.Type: ApplicationFiled: September 7, 2012Publication date: August 21, 2014Applicant: AMGEN INC.Inventors: Abraham Anderson, Kelly Oliner, Rui Tang, Elwyn Loh, Sarita Dubey
-
Publication number: 20140234208Abstract: Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.Type: ApplicationFiled: December 19, 2013Publication date: August 21, 2014Applicant: AbbVie, Inc.Inventors: Tariq GHAYUR, Junjian LIU, Peter C. ISAKSON
-
Patent number: 8808667Abstract: The present invention relates to the use of a milled homogenate and/or a suspension and/or a cell lysate, stemming from a tumor resistant to at least one anti-tumoral compound in order to immunize and generate in vitro an antibody, or one of its functional fragments, directed against a tumoral antigen specifically expressed at the surface of said resistant tumor and being possibly involved in the resistance of said resistant tumor. More particularly, the present invention is directed to such antibodies obtained by applying the method, such as the antibodies 1A6, 1A9, 2E11, 3C11 and 3G7, as well as to their use for treating cancer.Type: GrantFiled: July 9, 2012Date of Patent: August 19, 2014Assignee: Pierre Fabre MedicamentInventors: Liliane Goetsch, Alexandra Jouhanneaud
-
Publication number: 20140227256Abstract: The present invention is directed to methods for identifying which patients diagnosed with cancer will most benefit from treatment with an anti-cancer therapy comprising an ADCC-enhanced antibody.Type: ApplicationFiled: January 21, 2014Publication date: August 14, 2014Applicant: ROCHE GLYCART AGInventors: Lilla Di Scala, Stefan Evers, Christian Gerdes, Christoph Mancao, Alexandre Passioukov, Pablo Umana
-
Publication number: 20140227172Abstract: The methods of the present disclosure are directed toward methods of diagnosis and treatment of cancer in a subject. The present disclosure provides methods of diagnosing abnormal cells in a subject by measuring the level of Hexim-1 in a sample from the subject, where elevated levels of Hexim-1 indicate abnormal cells. This disclosure further provides methods of treating cancer or hyperplasia, comprising administering to a subject in need thereof a therapeutically effective amount of Hexim-1 or an activator of Hexim-1 expression or activity.Type: ApplicationFiled: March 22, 2012Publication date: August 14, 2014Applicant: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORKInventors: Manya Dhar-Mascareno, Eduardo J. Mascareno
-
Publication number: 20140227179Abstract: Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to an epitope located within the second to fourth cysteine-rich domains of MUC5ac (amino acid residues 1575-2052) and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay.Type: ApplicationFiled: April 1, 2014Publication date: August 14, 2014Applicant: IMMUNOMEDICS, INC.Inventors: Donglin Liu, David V. Gold, Chien-Hsing Chang, Serengulam V. Govindan, David M. Goldenberg
-
Publication number: 20140227284Abstract: Described herein are compounds, compositions and methods for treatment of cancer. Also described are methods and uses for identifying subject with cancer that are suitable for treatment with the compounds, composition and methods are described herein. In one aspect of the present invention, there is provided a method of treating a subject having a cancer deficient in NMT2, comprising: administering to said subject an NMT inhibitor.Type: ApplicationFiled: July 23, 2012Publication date: August 14, 2014Applicant: PACYLEX PHARMACEUTICALS INC.Inventors: Luc G. Berthiaume, Erwan Beauchamp, Conganige Maneka Anne Perinpanayagam, Chuiyee Yap
-
Publication number: 20140227276Abstract: The present invention relates to modulators of G protein-coupled receptor 177 (Gpr177) for use in the treatment, alleviation, prevention and/or diagnosis of cancer as well as to methods for the diagnosis of such cancer.Type: ApplicationFiled: April 18, 2012Publication date: August 14, 2014Applicants: RUPRECHT-KARLS-UNIVERSITAET-HEIDELBERG, DEUTSCHES KREBSFORSCHUNGSZENTRUMInventors: Michael Boutros, Iris Augustin
-
Publication number: 20140228441Abstract: The invention relates to compounds of formula (I), and the use thereof as a drug, particularly for the treatment of tumors associated with hyperactivation of the hedgehog protein signaling pathway, treatment of neurodegenerative diseases, treatment of diseases related to cerebral development (holoprosencephaly), for stem cell monitoring treatment of cerebrovascular accidents and cardiovascular accidents, treatment of diseases involving oligodendrocytes and diseases involving neurolemmocytes, for application thereof in vitro for modulating human or animal stem cell renewal, and for the treatment of diabetes. The invention also relates to pharmaceutical compositions having a compound of formula (I).Type: ApplicationFiled: September 21, 2012Publication date: August 14, 2014Applicants: Centre National De La Recherche Scientifique, Universite De StrasbourgInventors: Martial Ruat, Hélène Faure, Hermine Roudaut, Lucile Hoch, Angèle Schoenfelder, Maurizio Taddei, André Mann
-
Publication number: 20140228423Abstract: In embodiments of the present invention, there are methods and compositions related to diagnosis and treatment of serous ovarian cancer. In specific embodiments, the invention encompasses methods related to miR-34c in diagnosis and treatment methods for serous ovarian cancer. In specific embodiments, the invention encompasses treatment methods for pancreatic cancer and other responsive cancers.Type: ApplicationFiled: June 1, 2012Publication date: August 14, 2014Applicant: BAYLOR COLLEGE OF MEDICINEInventors: Martin M. Matzuk, Jaeyeon Kim, Zhifeng Yu
-
Publication number: 20140228233Abstract: Biomarkers can be assessed for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or the stage or progression of a disease, select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and to determine treatment efficacy. Circulating biomarkers from a bodily fluid can be used in profiling of physiological states or determining phenotypes. These include nucleic acids, protein, and circulating structures such as vesicles, and nucleic acid-protein complexes.Type: ApplicationFiled: June 7, 2012Publication date: August 14, 2014Inventors: Traci Pawlowski, Kimberly Yeatts, Ray Akhavan
-
Patent number: 8802382Abstract: The present invention provides a specific binding partner for holoTC having a specificity for holoTC over apoTC of at least 40-fold and an assay method for assaying for holoTC in a sample, the method comprising contacting the sample with a specific binding partner for holoTC and detecting the resultant conjugates.Type: GrantFiled: December 23, 2013Date of Patent: August 12, 2014Assignee: Axis-Shield ASAInventors: Lars Orning, Anne Rian
-
Patent number: 8802088Abstract: The present invention relates to a composition which comprises tryptophan whereby 10 to 90%, preferably 20 to 80% of the tryptophan is present as free tryptophan or peptide-bound tryptophan and 10 to 90%, preferably 20 to 80% of the tryptophan is present as polypeptide-bound tryptophan.Type: GrantFiled: April 27, 2009Date of Patent: August 12, 2014Assignee: DSM IP Assets B.V.Inventors: Cinderalla C. Gerhardt, Luppo Edens
-
Patent number: 8802383Abstract: The technology relates to monoclonal antibodies useful in the identification of cancer cells. In one embodiment, mAbs with specificity for tumor antigens are provided. In one embodiment, methods for treating cancer using mAbs are provided. In another embodiment, methods for detecting cancerous cells are provided. In another embodiment, kits for detecting cancerous cells are provided.Type: GrantFiled: May 16, 2012Date of Patent: August 12, 2014Assignee: Sanofi Pasteur LimitedInventors: Neil Berinstein, Devender Satsangi Singh Sandhu, Corey Lovitt, Artur Pedyczak, Scott Gallichan, Laszlo Radvanyi
-
Patent number: 8802384Abstract: The present invention relates to biomarkers to monitor the activity of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone or a pharmaceutically acceptable salt thereof, and especially its monoethanesulphonate salt form, when used alone or optionally in combination with further pharmaceutically active ingredients and/or further treatments, such as for example radiotherapy.Type: GrantFiled: March 9, 2010Date of Patent: August 12, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Tokuzo Arao, Kanae Kudo, Kazuhiko Nakagawa, Kazuto Nishio
-
Publication number: 20140220597Abstract: The present invention relates to the prognosis, therapeutic stratification and treatment of colorectal cancer. More in particular, the present invention discloses that significantly increased levels of transmembrane type 1 neuregulin-1 in tumor-associated mesenchymal cells present in a sample of a patient indicate that the patient has a worse prognosis when compared to patients having low levels of transmembrane type 1 neuregulin-1 in tumor-associated mesenchymal cells. Moreover, the present invention relates to the usage of transmembrane type 1 neuregulin-1 expression in tumor-associated mesenchymal cells to predict resistance to HER1 inhibitors during colorectal cancer therapy and/or to predict whether a patient would benefit from a therapy based on the prevention of neuregulin-1 and/or HER3 activity.Type: ApplicationFiled: September 12, 2012Publication date: August 7, 2014Applicant: UNIVERSITEIT GENTInventors: Olivier De Wever, Astrid De Boeck
-
Publication number: 20140219978Abstract: The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.Type: ApplicationFiled: December 13, 2013Publication date: August 7, 2014Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Nicholas P. Restifo, Lydie Cassard, Zhiya Yu, Steven A. Rosenberg
-
Publication number: 20140220018Abstract: Disclosed herein are methods for diagnosing the state of an epithelial tumor or tissue in a subject. Also disclosed are methods of diagnosing tumor initiation in an epithelial tissue of a subject. Also disclosed are methods of determining prognosis of a subject with an epithelial tumor. These methods include, in part, measuring the amount of pSer239-VASP, pSer157-VASP, and/or total VASP in a subject or in a tissue or tumor of a subject and comparing those levels to an appropriate reference level. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: June 16, 2012Publication date: August 7, 2014Inventors: Giovanni M. Pitari, David S. Zuzga
-
Publication number: 20140220016Abstract: Methods of inhibiting the growth of tumors comprising administering chimeric fusion molecules comprising endostatin mutants and all or a portion of anti-Her2 or anti-EGFR antibodies.Type: ApplicationFiled: April 16, 2014Publication date: August 7, 2014Applicant: University of MiamiInventors: Seung-Uon Shin, Joseph David Rosenblatt, Sherie L. Morrison
-
Publication number: 20140221244Abstract: The invention provides methods, compositions and kits relating to the detection, diagnosis, treatment of colorectal cancer.Type: ApplicationFiled: August 31, 2012Publication date: August 7, 2014Inventors: Karen Chapman, Joseph Wagner, Michael West, Markus Daniel Lacher, Jennifer Lorie Kidd, Maria Prendes
-
Publication number: 20140220003Abstract: The present invention relates to a therapeutic method and a diagnostic method using an antibody that binds to a ganglioside GM2 antigen, and a therapeutic agent and a diagnostic agent comprising as an active ingredient an antibody that binds to a ganglioside GM2 antigen. According to the present invention, the prognosis of GM2 positive mesothelioma patients can be improved by diagnosing and treating GM2 positive mesothelioma patients with a diagnostic agent and a therapeutic agent that comprise an anti-ganglioside GM2 antibody as an active ingredient.Type: ApplicationFiled: December 5, 2013Publication date: August 7, 2014Applicants: KYOWA HAKKO KIRIN CO., LTD, NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITYInventors: Seiji YANO, Yusuke MACHINO, Yui SUZUKI